Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 15/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618675 | 1.00 | CHRM1 (0.42) | CHRM1CHRM4CHRM5GRM5L3MBTL1 | |
| SCHEMBL3745563 | 0.93 | MAPK1 (0.48) | CHRM1CHRM4CHRM5GRM5L3MBTL1 | |
| SCHEMBL20942090 | 0.88 | KDM4E (0.37) | CHRM1CHRM4CHRM5GRM5CHRM2 | |
| SCHEMBL29650103 | 0.85 | SMN1; SMN2 (0.42) | CHRM1GRM5L3MBTL1CHRM2CHRM3 | |
| SCHEMBL5317376 | 0.85 | SMN1; SMN2 (0.42) | CHRM1GRM5L3MBTL1CHRM2CHRM3 | |
| SCHEMBL21597914 | 0.84 | CHRM1 (0.40) | CHRM1CHRM4CHRM5GRM5L3MBTL1 | |
| SCHEMBL12873753 | 0.81 | GRM5 (0.42) | CHRM1GRM5CHRM2CHRM3MAPK1 | |
| SCHEMBL11731279 | 0.81 | GRM5 (0.42) | CHRM1GRM5CHRM2CHRM3MAPK1 | |
| SCHEMBL2148232 | 0.81 | CHRM1 (0.41) | CHRM1CHRM4CHRM5GRM5CHRM2 | |
| SCHEMBL20942086 | 0.81 | SLC6A3 (0.33) | CHRM1CHRM2CHRM3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| EP-3638658-B1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-10-08 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
| EP-4413985-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| US-20240165097-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR DEMENTIA | NXERA PHARMA UK LIMITED (GB) | 2024-05-23 | — | — | US | disclosed |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-5663182-A | ADMINISTERING AN AZABICYCLIC RING SUBSTITUTED THIADIAZOLE OR OXADIAZOLE TO A MAMMAL | BYMASTER FRANKLIN PORTER (US) | 1997-09-02 | — | — | US | disclosed |
| US-5641791-A | USEFUL AS STIMULANTS OF COGNITIVE FUNCTION OF FOREBRAIN AND HIPPOCAMPUS OF MAMMALS AND IN THE TREATMENT OF ALZHIEMER'S DISEASE, SEVERE PAIN AND GLAUCOMA | NOVO NORDISK A.S (DK) | 1997-06-24 | — | — | US | disclosed |
| US-5612351-A | AZABICYCLIC DERIVATIVES OF 1,2,3-OXA(OR THIA)DIAZOLE | NOVO NORDISK A/S (DK) | 1997-03-18 | — | — | US | disclosed |
| US-5578602-A | FOR STIMULATING COGNITIVE FUNCTIONS OF THE BRAIN, TREATING ALZHEIMER*S DISEASE, GLAUCOMA OR PAIN | NOVO NORDISK A/S (DK) | 1996-11-26 | — | — | US | disclosed |
| US-5574043-A | ALZHEIMERS, GLAUCOMA, ANALGESIC | NOVO NORDISK A/S (DK) | 1996-11-12 | — | — | US | disclosed |
| US-5527813-A | THERAPEUTICALLY ACTIVE AZABICYCLIC COMPOUNDS USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND IN THE TREATMENT OF ALZHEIMER'S DISEASE | NOVO NORDISK A/S (DK) | 1996-06-18 | — | — | US | disclosed |
| US-5260314-A | Cognition activators, glaucoma analgesic | NOVO NORDISK A/S (DK) | 1993-11-09 | — | — | US | disclosed |
| EP-0544779-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992003433-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-03-05 | — | — | WO | disclosed |
| US-4277472-A | 3,6-Disubstituted-5,7-(lower alkano)-5,6,7,8-tetrahydropyrido(4,3-C)pyridazines; their intermediates, preparation, antihypertensive use and compositions | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM4 5/4885CHRM5 4/4885 |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885CHRM4 3/4885CHRM5 4/4885 |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | CHRM1 3653/4885CHRM4 4014/4885CHRM5 3223/4885 |
| US-20240165097-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR DEMENTIA | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885CHRM4 3/4885CHRM5 4/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | CHRM1 3653/4885CHRM4 4014/4885CHRM5 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.